Newark, DE, U.S. and Nanjing, China – January 3, 2022.  Biosion, Inc. (“Biosion”), a global clinical stage biotechnology company, today announced the appointment of Dr. Anthony Yeh to the position of Chief Strategy Officer and Head of China business development (BD), where he will lead corporate strategy, China BD, and capital fundraising. He will report to Dr. Mingjiu Chen, Chief Executive Officer (CEO). Prior to joining Biosion, Dr. Yeh was most recently Vice President, Head of Corporate Strategy, Investor Relations and Capital Market at CStone Pharmaceuticals (HKSE:2616).

“We are pleased to welcome Anthony to Biosion as we continue to expand globally and strengthen our executive leadership,” said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion. “With the unique combination of cross-cultural background, outstanding scientific training, and extensive experience in the biopharma industry, Anthony represents the next generation of leaders who are the driving force for the globalization of China-based innovation. We look forward to his leadership as we advance toward our vision of delivering breakthrough biologics to patients worldwide.”

“Since I came back to China in 2007, China’s biopharmaceutical industry has undergone a momentus shift, from biosimilar-focused into one that nurtures innovation, and from domestic-focused into one that pivots towards globalization,” said Dr. Yeh. “Based on its global development capabilities, proprietary discovery platforms, and rich pipeline of innovative biologics, Biosion is becoming the front runner leading the next wave of China biopharmaceutical industry evolution. I look forward to joining Biosion’s world-class team to expand its global partnerships and accelerate global capital access.”

Dr. Yeh brings to Biosion over 15 years of experience in healthcare, investment, and management consulting. During his tenure at CStone Pharmaceuticals (HKSE: 2616), Dr. Yeh served several different leadership roles in helping to build CStone through public listing and eventually to commercialization stage. Prior to CStone, Dr. Yeh was Regional Head of Business Economics and Strategy at Abbott (NYSE: ABT) and engagement manager at L.E.K. Consulting where he specialized in life sciences strategy and M&A. Dr. Yeh holds a Ph.D. in Molecular Medicine from University of Oxford and a Bachelor of Science (honors) from Queensland University of Technology.